Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TreeTopp: Varlitinib + Capecitabine in 2L Biliary Tract Cancer
NCT03093870Phase 3Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Nov 2019
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of varlitinib in biliary tract cancer (BTC), sponsored by ASLAN Pharmaceuticals. Started Jul 2017; status: completed.
02
Drugs
varlitinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03093870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093870.